Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

NCT03335241 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Fludarabine and Pegylated liposomal doxorubicin
DRUG: Pegylated liposomal doxorubicin

Sponsor

Sun Yat-sen University